Repeated allergen exposure changes collagen composition in airways of sensitised Brown Norway rats.
Increased or altered collagen deposition in the airway wall is one of the characteristics of airway remodelling in asthma. The mechanisms underlying this increase, and its functional consequences remain to be established further. Representative in vivo animal models might be useful in this respect. In the present study, collagen deposition after prolonged allergen exposure was characterised in the airway wall of Brown Norway rats. Sensitised rats were repeatedly exposed to ovalbumin (OA) or phosphate-buffered saline during 2 and 12 weeks. The deposition of collagen type I, III, IV, V and VI was not altered in animals exposed to OA for 2 weeks. After 12 weeks of OA exposure, more collagen type I was deposited in the inner and outer airway wall and more type V and VI collagen was observed in the outer airway wall. At 12 weeks the number of vessels, identified via type IV collagen staining was not increased, but the total vessel area was. In conclusion, prolonged allergen exposure in sensitised rats is associated with enhanced deposition of type I, V and VI collagens and increased vascularity. This suggests that some aspects of airway remodelling in asthma could be driven by long-term allergen exposure.
Palmans
E
E
Dept of Respiratory Diseases, Ghent University Hospital, Belgium. els.palmans@hogent.be
Pauwels
R A
RA
Kips
J C
JC
D000485:Allergens / Q000008:administration & dosage* / Q000276:immunology / Q000494:pharmacology*; D000818:Animals; D001249:Asthma / Q000276:immunology / Q000473:pathology*; D024141:Collagen Type IV / Q000032:analysis* / Q000187:drug effects* / Q000276:immunology; D024142:Collagen Type VI / Q000032:analysis* / Q000187:drug effects* / Q000276:immunology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D024022:Fibrillar Collagens / Q000032:analysis* / Q000187:drug effects* / Q000276:immunology; D007114:Immunization; D008168:Lung / Q000187:drug effects* / Q000276:immunology / Q000473:pathology*; D008297:Male; D010047:Ovalbumin / Q000008:administration & dosage* / Q000276:immunology / Q000494:pharmacology*; D051381:Rats; D013997:Time Factors
D000485:Allergens; D024141:Collagen Type IV; D024142:Collagen Type VI; D024022:Fibrillar Collagens; D010047:Ovalbumin